Long term survival and complications after liver transplantation in patients with chronic hepatitis B

Annals of Transplantation

Volumn 15, Issue 2, 2010, Pages 27-34

  Yataco, Maria ^a   Bonatti, Hugo ^a,b   Machicao, Victor ^a,c   Mendez, Julio ^a   Stauffer, John ^a   Nguyen, Justin ^a   Ghabril, Marwan ^a,d   Aranda Michel, Jaime ^a   Dickson, Rolland C ^a,e  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

HBV; Hepatocellular cancer; Immunosuppression; Lamivudine; Liver transplant

Indexed keywords

ACICLOVIR; ADEFOVIR; ALPHA2B INTERFERON; AMPHOTERICIN B LIPID COMPLEX; AZATHIOPRINE; CEPHALOSPORIN; COTRIMOXAZOLE; CYCLOSPORIN A; ENTECAVIR; GANCICLOVIR; HEPATITIS B ANTIBODY; LAMIVUDINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; STEROID; TACROLIMUS; ADENINE; ANTIVIRUS AGENT; HEPATITIS B HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; PHOSPHONIC ACID DERIVATIVE;

ACUTE GRAFT REJECTION; ADULT; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL INFECTION; CHRONIC KIDNEY FAILURE; COMORBIDITY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; FEMALE; HEPATITIS B; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MYCOSIS; OBESITY; PNEUMOCYSTIS PNEUMONIA; POSTOPERATIVE COMPLICATION; SURVIVAL TIME; TUMOR RECURRENCE; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; COHORT ANALYSIS; COMPLICATION; GRAFT SURVIVAL; HEPATITIS B, CHRONIC; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; SECONDARY PREVENTION; TREATMENT OUTCOME;

ADENINE; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; GRAFT SURVIVAL; HEPATITIS B, CHRONIC; HUMANS; IMMUNOGLOBULINS; KAPLAN-MEIER ESTIMATE; LAMIVUDINE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 77954628255     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Burroughs AK, Sabin CA, Rolles K et al: 3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for out-come. Lancet, 2006; 367(9506): 225-32.
2. Kotlyar DS, Campbell MS, Reddy KR: Recurrence of diseases following orthotopic liver transplanta-tion. Am J Gastroenterol. 2006; 101(6): 1370-78.
3. Mehrabi A, Fonouni H, Muller SA, Schmidt J: Current concepts in transplant surgery: liver trans-plantation today. Langenbecks Arch Surg, 2008; 393(3): 245-60.
4. Van Thiel DH, Schade RR, Gavaler JS, Shaw BW Jr et al: Medical aspects of liver transplantation. Hepatology, 1984; 4(1 Suppl.): 79S-83S
5. O'Grady JG, Smith HM, Davies SE et al: Hepatitis B virus reinfection after orthotopic liver trans-plantation. Serological and clinical implications. J Hepatol, 1992; 14(1): 104-11.
6. Todo S, Demetris AJ, Van Thiel D et al: Orthotopic liver transplantation for patients with hepatitis B vi-rus-related liver disease. Hepatology, 1991; 13(4): 619-26.
7. Han SH, Ofman J, Holt C et al: An efficacy and cost-effectiveness analysis of combination hepati-tis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver trans-plantation compared with hepatitis B immune globulin monotherapy. Liver Transpl, 2000; 6(6): 741-48.
8. Seehofer D, Rayes N, Steinmuller T et al: Combination prophylaxis with Hepatitis B immu-noglobulin and lamivudine after liver transplan-tation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance. Z Gastroenterol, 2002; 40(9): 795-99.
9. Yao FY, Osorio RW, Roberts JP et al: Intramuscular hepatitis B immune globulin combined with lam-ivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg, 1999; 5(6): 491-96.
10. Yoshida EM, Erb SR, Partovi N et al: Liver trans-plantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg, 1999; 5(6): 520-25.
11. Angus PW, McCaughan GW, Gane EJ et al: Combination low-dose hepatitis B immune glob-ulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl, 2000; 6(4): 429-33.
12. Marzano A, Salizzoni M, Debernardi-Venon W et al: Prevention of hepatitis B virus recurrence af-ter liver transplantation in cirrhotic patients treat-ed with lamivudine and passive immunoprophy-laxis. J Hepatol, 2001; 34(6): 903-10.
13. Kim WR, Poterucha JJ, Kremers WK et al: Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl, 2004; 10(8): 968-74.
14. Obed A, Tsui TY, Schnitzbauer AA et al: Liver trans-plantation as curative approach for advanced hepa-tocellular carcinoma: is it justified? Langenbecks Arch Surg, 2008; 393(2): 141-47.
15. Tzakis A, Todo S, Starzl TE: Orthotopic liver trans-plantation with preservation of the inferior vena cava. Ann Surg, 1989; 210(5): 649-52.
16. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology, 1997; 25(3): 658-63.
17. Hellinger WC, Bonatti H, Yao JD et al: Risk strat-ification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation. Liver Transpl, 2005; 11(6): 656-62.
18. Hellinger WC, Bonatti H, Machicao VI et al: Effect of antiviral chemoprophylaxis on adverse clinical outcomes associated with cytomegalovirus after liv-er transplantation. Mayo Clin Proc, 2006; 81(8): 1029-33.
19. Yao FY, Ferrell L, Bass NM et al: Liver transplan-tation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology, 2001; 33(6): 1394-403.
20. Mazzaferro V, Regalia E, Doci R et al: Liver trans-plantation for the treatment of small hepatocellu-lar carcinomas in patients with cirrhosis. N Engl J Med, 1996; 334(11): 693-99.
21. Roche B, Samuel D: Liver transplantation for hep-atitis B virus-related liver disease: indications, pre-vention of recurrence and results. J Hepatol, 2003; 39(Suppl.1): S181-89.
22. Feng S, Goodrich NP, Bragg-Gresham JL et al: Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant, 2006; 6(4): 783-90.
23. Machicao VI, Bonatti H, Krishna M et al: Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation, 2004; 77(1): 84-92.
24. Broelsch CE, Frilling A, Malago M: Should we ex-pand the criteria for liver transplantation for hepa-tocellular carcinoma-yes, of course! J Hepatol, 2005; 43(4): 569-73.
25. Sutcliffe R, Maguire D, Portmann B et al: Selection of patients with hepatocellular carcinoma for liver transplantation. Br J Surg, 2006; 93(1): 11-18.
26. Chen CJ, Yang HI, Su J et al: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama, 2006; 295(1): 65-73.
27. Prevention of primary liver cancer: Report on a meeting of a W.H.O. Scientific Group. Lancet, 1983; 1(8322): 463-65.
28. Park NH, Song IH, Chung YH: Chronic hepatitis B in hepatocarcinogenesis. Postgrad Med J, 2006; 82(970): 507-15.
29. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med, 2005; 352(26): 2673-81.
30. Lo CM, Liu CL, Lau GK et al: Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl, 2005; 11(7): 807-13.
31. Buti M, Mas A, Prieto M et al: A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol, 2003; 38(6): 811-17.
32. Papatheodoridis GV, Sevastianos V, Burroughs AK: Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucle-oside analogues era. Am J Transplant, 2003; 3(3): 250-58.
33. Seaberg EC, Belle SH, Beringer KC et al: Liver transplantation in the United States from 1987-1998: updated results from the Pitt-UNOS Liver Transplant Registry. Clin Transpl, 1998; 17-37.
34. Screening for chronic hepatitis B among Asian/ Pacific Islander populations-New York City, 2005. MMWR Morb Mortal Wkly Rep, 2006; 55(18): 505-9.
35. Lee WM: Hepatitis B virus infection. N Engl J Med, 1997; 337(24): 1733-45.
36. Poland GA, Jacobson RM: Clinical practice: pre-vention of hepatitis B with the hepatitis B vaccine. N Engl J Med, 2004; 351(27): 2832-38.
37. Kim WR: Epidemiology of hepatitis B in the United States. Hepatology, 2009; 49(5 Suppl.): S28-34.
38. Katz LH, Paul M, Guy DG, Tur-Kaspa R: Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, an-tiviral drugs, or both? Systematic review and me-ta-analysis. Transpl Infect Dis, 2009 [Epub ahead of print]
39. Scherer MN, Banas B, Mantouvalou K et al: Current concepts and perspectives of immunosuppression in organ transplantation. Langenbecks Arch Surg, 2007; 392(5): 511-23